The aim of the present study was to analyze our experience with a new liquid embolic agent, Squid, for the treatment of cerebral vascular lesions.
Preliminary experience with Squid: A New Liquid embolizing Agent for AvM, Av Fistulas and Tumors

Squid Kullanımı ile İlgili İlk Deneyim: AVM, AV Fistül ve Tümör Tedavisinde Yeni Bir Sıvı Embolizan Ajan introduction
Percutaneous endovascular interventions with liquid embolic agents are used either as a primary treatment of cerebrovascular arteriovenous malformation (AVM) and aneurysms or as adjuncts to surgery and/or gamma knife treatment (2, 13). When embolization is considered as a primary treatment modality, obliteration rates of no more than 50% can be achieved (18) . Generally liquid embolic agents such as N-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) are used for the endovascular management of cerebral AVMs. The use of EVOH copolymers in AVMs was first reported by Terada et al. (15) . Later, Onyx was introduced and more widely used due to its slow polymerization and nonadhesive properties providing prolonged embolization times during the procedure (7,12).
Akmangit I. et al: Squid: A New Liquid Embolizing Agent
Squid® is an EVOH copolymer that has become available recently. It also has a less viscous formulation (Squid 12) for improved vascular penetration and as a lower density formulation (Squid LD) compared to Onyx. In the present study, we present the first treatment experience with this new embolic agent on 28 patients.
material and methodS
Study Design and Clinical Characteristics
We evaluated 28 consecutive patients who were treated with Squid®(Emboflu, Switzerland) between February 2013 and December 2013 by our neurovascular team in 2 hospitals in the present study.
There were 18 female and 10 male patients. The mean age 41 years, varying between 15 and 68 years. The study population included 16 AVMs, 9 arteriovenous (AV) fistulas (6 dural and 3 spinal), 2 tumors and 1 cerebral aneurysm, all of which were treated with Squid as the embolic agent. In 5 of these cases, the initial plug formed by the embolic agent was enhanced with an injection of glue proximally to block the retrograde (proximal) reflux of the embolic agent over the catheter. Among the 16 AVMs, 6 presented with hemorrhage, 6 with headache, 2 with syncope, 1 with tinnitus and 1 was a recurrent lesion. The AVMs were located in the frontal lobe in 4, temporal lobe in 4, thalamochoroidal area in 3, cerebellum in 2, occipital lobe in 1, posterior fossa/ventricle in 1, and orbit in 1 patient.
The Spetzler-Martin grade of the AVMs was 2 in eight, 3 in six and 4 in two patients. Of the 9 cerebral or spinal dural AV fistulas 2 presented with intracerebral hemorrhage, 2 with headache, 1 with tinnitus, 1 with residual fistula, 2 with paraparesis and 1 with radicular pain. The cerebral dural fistulas were located in the anterior fossa in 2, transverse sinus in 2, superior sagittal sinus in 1 and tentorium in 1 patient. Two patients were classified as 2a, two as 2b and another two as type 4 according to the Cognard classification. The diagnosis of the three remaining patients was glomus caroticum, nasopharyngeal angiofibroma and ruptured dissecting AICA aneurysm.
Technique of Embolization
Sessions of Squid embolization were all performed under general anesthesia on a monoplane (Innova GE, USA) or biplane (Artis Zee Siemens, Erlangen, Germany) angiography unit. A 6 French (F) guiding sheath -guiding catheter coaxial system was introduced into the carotid or vertebral arteries through a common femoral artery approach and under systemic heparinization. Then the target feeder artery was catheterized with a dimethyl sulfoxide (DMSO)-compatible detachable tip micro catheter (Sonic 1.2F or 1.5F, Balt, Montmercy, France) over a 0.007 or 0.008 inch microguidewire (Hybrid Balt, Montmercy, France). Angiographic confirmation of the tip of the microcatheter was performed and the vascular angioarchitecture was delineated for safe embolization. Before Squid injection, the microcatheter was flushed with 5 ml saline and its dead space was filled with 0.35 ml DMSO. The same volume of Squid was injected slowly for 45 seconds to substitute the DMSO in the dead space. Squid was meticulously injected into the lesion under the roadmap. The injection was stopped every 2-3 minutes to reset the roadmap. After some forward penetration, there was a tendency of Squid to reflux into the feeding artery forming a plug. Once a solid plug was formed, forward penetration of Squid into the lesion was noted (plug and push technique). Squid 12 or 18 was used depending on the degree of shunt in the AVM at the beginning. After making sure that no Squid escaped into the vein with the first injection, Squid 12 was used for further embolization due to its ability to penetrate more distally within the formed cast. The embolization was discontinued when the reflux reached the detachment zone of the microcatheter or when embolization was completed through the involved arterial pedicle. As noted above, additional glue was injected proximally in an effort to prevent further backward flow of Squid, after formation of the Squid plug in 5 cases. After complete embolization of the involved artery or lesion itself, the microcatheter was gently removed with application of gradual backward tension to achieve safe microcatheter removal. All Sonic microcatheters were successfully removed without sequela.
reSultS
Complete obliteration of the AVM was achieved in 6 patients (37.5% of all AVMs) at the end of the endovascular treatment ( Figure 1A-D) . In 5 patients (31.2%), 75% or more reduction was achieved in the size of the AVMs and the residual lesion was amenable to radiosurgery. Preoperative embolization was performed to obtain volumetric reduction of the AVM and to reduce the risk of intraoperative bleeding in 2 patients (12.5%). Intraprocedural transient leak of contrast agent was detected in 2 patients (12.5%) during Squid embolization. In 1 (6.25%) of these patients the hematoma was resected with surgery. This patient had a modified Rankin score of 2 on follow-up. Another patient had aphasia due to a periprocedural thromboembolic event that markedly improved on follow-up. One patient's therapy is continuing.
The sections were stained with hematoxylin-eosin and Verhoeff-van Gieson for pathology examinations and revealed mild inflammatory reaction with infiltration of polymorphonuclear cells in 5 patients in whom surgery was performed immediately after the embolization. Infiltration of giant cells and mononuclear cells was noted in another patient who had undergone delayed surgical excision.
Total obliteration was achieved in 4 patients (66%) with cerebral dural AV fistulas (Figure 2A-D) . Surgery was performed and resulted in cure in 2 of these patients where small residual feeders from the cavernous ICA remained after embolization. One patient had a significant reduction of a Vein of Galen dural AVF previously treated by focal injection of glue and was subsequently referred to radiosurgery for the small residual supply. One patient is awaiting a second session of embolization. Figure 3A-D) .
Preoperative embolization was also performed with Squid in two more patients with glomus caroticum and nasopharyngeal angiofibroma. The surgery was uneventful and without significant blood loss in both.
Unintended partial venous embolization of Squid during injection was observed in 1 patient. The average volume of Squid injected was 3 ml per nidus. The mean duration of injection was 46 minutes. There was no mortality in the 28 patients included in the study. There were no retained, ruptured or prematurely clogged microcatheters.
diScuSSion
In the present study, we presented the first experience with the clinical use of a new EVOH copolymer, Squid. efficiently through the embolic cast than Squid 18. In our experience, Squid 18 behavior was very similar to Onyx 18.
Complete and easy removal of the microcatheter without separation from the detachment zone was not uncommon in the present series though the number of such cases was not recorded. We did not have any stuck microcatheters after embolization. A stuck or retained microcatheter used to be a problem before the introduction of detachable tip microcatheters. Nevertheless, retained catheters are still a potential problem that may have been underreported despite the use of detachable tip microcatheters.
Premature obliteration of the microcatheter lumen, stranding at the tip of the microcatheter during withdrawal (5), and catheter entrapment despite the use of detachable tip catheters (1, 9,18) are potential adverse events observed during EVOH embolizations. We did not encounter such problems in this preliminary series.
Hemorrhage during or soon after embolization is an unintended and feared complication and might be experienced in up to 17% of the cases despite all precautions (7,10-12,17) and prompt surgical intervention may be needed if bleeding does not cease. In the present series, the rate of intracranial hemorrhage during AVM treatment was reported to be 12.5% and the symptomatic hemorrhage rate was 6.25%. AVM obliteration was complete in 6 of the 16 cases (37.5%). These findings are in accordance with the results of the current Onyx series reported in the literature (18) . Similarly, our total obliteration rate for dural AVFs and spinal AVFs in the absence of any permanent deficit were also satisfactory.
Distal AICA aneurysms are rare (4). Patients usually present with lower cranial nerve palsies (14) . Trauma may play role in the pathogenesis of AICA aneurysms and clipping is not feasible due to the dissecting nature of these aneurysms (6, 8). Thus, parent artery occlusion is also an optional treatment for these lesions. To our knowledge, this is the first AICA aneurysm treated with a liquid embolizing agent.
Embolization is useful in hypervascular tumoral lesions to decrease the operative life-threatening bleeding risk and operation time (16). PVA, n-BCA and Onyx have been frequently used agents for tumor embolization. Angiofibroma and glomus tumors are among the most commonly embolized tumors due to their vascular nature (3). Squid was successfully used for embolization of two tumoral lesions and near complete embolization was achieved without any complication.
concluSion
We presented the first experience with Squid in the treatment of AVMs, AVFs, aneurysms and tumors. We conclude that Squid is as safe and effective as its predecessor. In our experience the lower viscosity formulation (Squid 12) enabled better penetration as compared to Squid 18 or Onyx formulations.
